Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Iovance Biotherapeutics (IOVA) Leases (2019 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Leases for 4 consecutive years, with $45.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases fell 16.85% to $45.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $45.9 million, a 16.85% decrease, with the full-year FY2025 number at $45.9 million, down 16.85% from a year prior.
  • Leases was $45.9 million for Q4 2025 at Iovance Biotherapeutics, down from $48.8 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $71.5 million in Q1 2024 to a low of $45.9 million in Q4 2025.
  • A 3-year average of $58.9 million and a median of $58.9 million in 2023 define the central range for Leases.
  • Peak YoY movement for Leases: increased 1.54% in 2024, then fell 28.82% in 2025.
  • Iovance Biotherapeutics' Leases stood at $62.5 million in 2023, then decreased by 11.7% to $55.2 million in 2024, then dropped by 16.85% to $45.9 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Leases are $45.9 million (Q4 2025), $48.8 million (Q3 2025), and $49.9 million (Q2 2025).